Global oncology innovator,
BeiGene, Ltd. presented at the
Jefferies London Healthcare Conference and revealed their innovative
hematology portfolio at ASH 2024. However, BeiGene is facing litigation by
AbbVie over alleged theft of cancer therapy secrets. Investment is rising in BeiGene with
XY Capital Ltd and
Asset Management One Co. Ltd., taking positions. Equally, the company's shares rallied in Q3, and they saw a 5.3% increase in shares. New Board appointment includes
Aaron Rosenberg as CFO even though BeiGene mourns the passing of board member Donald Glazer. BeiGene has received positive reviews from
CHMP for
TEVIMBRA, an advanced metastatic cancer treatment. The company's shares have surged by 32% in a month, and their operations are expanding worldwide. Analysts predict a 27.84% upside in BeiGene's shares. Furthermore, BeiGene's FDA-approved esophageal cancer therapy,
Tislelizumab, has also met Israeli approval. They announced an EGM record date for domicile shift and reported strong revenue growth in recent reports.
BeiGene, Ltd. News Analytics from Tue, 23 Jan 2024 08:00:00 GMT to Sun, 10 Nov 2024 00:41:47 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -5
